Chalmers Researchers Find FMN Reduces Alzheimer's Peptide Toxicity

Scientists at Chalmers University of Technology in Sweden have discovered a potential new approach in combating Alzheimer's disease. Their research indicates that flavin mononucleotide (FMN), an active form of riboflavin (Vitamin B2), can significantly decrease the toxicity of amyloid-beta (Aβ) peptides, which are central to the disease's development.

In Alzheimer's, a progressive and incurable neurodegenerative condition, the misfolding and aggregation of Aβ peptides are considered primary drivers. These processes lead to neuronal dysfunction and cell death in the brain. The study, published in Nature Communications, utilized yeast as a model organism to demonstrate the effects of FMN supplementation.

The researchers observed that in yeast cells producing the toxic Aβ42 peptide, FMN supplementation reduced levels of misfolded proteins and enhanced the cells' resistance to oxidative stress. This is significant as brain cells are particularly vulnerable to oxidative stress, which can worsen Alzheimer's progression.

The study also found that deletion of the FMN1 gene in yeast increased Aβ42 toxicity, pointing to the importance of riboflavin metabolism. Given that humans have a homologous gene to FMN1 linked to Alzheimer's and riboflavin has been previously suggested as a neuroprotective agent, this finding presents promising directions for developing new treatments.

Future research will focus on testing the benefits of FMN supplementation in other Alzheimer's model organisms and further investigating its effects for other neurodegenerative diseases, such as Huntington's and Parkinson's disease.